Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

With DIVISLAB's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.000000
forwardPE 55.090874
debtToEquity 0.027000
earningsGrowth 0.265000
revenueGrowth 0.138000
grossMargins 0.603400
operatingMargins 0.256020
trailingEps 86.610000
forwardEps 56.300000

DIVISLAB's elevated forward PE ratio suggests limited upside potential and a risk of price correction. Investors must scrutinize this metric closely, ensuring it aligns with other fundamental indicators before making any decisions.
DIVISLAB's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
With positive gross and operating margins, DIVISLAB's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
DIVISLAB's forward EPS, being lower than its trailing EPS, points to an expected decline in profitability. This suggests that the company's financial performance may weaken in the upcoming year.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

DIVISLAB's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


19 transactions were made to sell Divi's Laboratories Limited shares, with market price of 5869.189478824013.2 transactions to buy DIVISLAB shares were recorded, with market price at 5854.875.The transactions conducted by insiders do not indicate any significant pattern, leaving little to infer about the company’s strategic moves.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


With analysts showing a sell bias toward DIVISLAB, it's crucial for investors to approach decisions carefully. It's recommended to consult a broader base of market indicators rather than relying solely on the analysts' bias, as this will offer a more comprehensive view of the stock's prospects.